Australien - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 14 g/l; arginine, quantity: 12 g/l; glycine, quantity: 11 g/l; histidine, quantity: 3 g/l; isoleucine, quantity: 5 g/l; leucine, quantity: 7.4 g/l; lysine acetate, quantity: 9.31 g/l (equivalent: lysine, qty 6.6 g/l); methionine, quantity: 4.3 g/l; phenylalanine, quantity: 5.1 g/l; proline, quantity: 11.2 g/l; serine, quantity: 6.5 g/l; taurine, quantity: 1 g/l; threonine, quantity: 4.4 g/l; tryptophan, quantity: 2 g/l; tyrosine, quantity: 400 mg/l; valine, quantity: 6.2 g/l - injection, solution - excipient ingredients: glacial acetic acid; water for injections - to supply amino acids as part of a composite admixture of total parenteral nutrition.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 14 g/l; arginine, quantity: 12 g/l; glycine, quantity: 11 g/l; histidine, quantity: 3 g/l; isoleucine, quantity: 5 g/l; leucine, quantity: 7.4 g/l; lysine acetate, quantity: 9.31 g/l (equivalent: lysine, qty 6.6 g/l); methionine, quantity: 4.3 g/l; phenylalanine, quantity: 5.1 g/l; proline, quantity: 11.2 g/l; serine, quantity: 6.5 g/l; taurine, quantity: 1 g/l; threonine, quantity: 4.4 g/l; tryptophan, quantity: 2 g/l; tyrosine, quantity: 400 mg/l; valine, quantity: 6.2 g/l - injection, solution - excipient ingredients: glacial acetic acid; water for injections - to supply amino acids as part of a composite admixture of total parenteral nutrition.

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

ferring pharmaceuticals ltd - atosiban acetate - solution for infusion - 7.5mg/1ml

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - glucose monohydrate; sodium chloride; sodium gluconate; potassium chloride; sodium acetate trihydrate; magnesium chloride hexahydrate - infusion - 55gram/1litre ; 5.26gram/1litre ; 5.02gram/1litre ; 370mg/1litre ; 3.68gram/1litre ; 300mg/1litre

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - potassium chloride; sodium chloride; glucose monohydrate; sodium gluconate; magnesium chloride hexahydrate; sodium acetate trihydrate - infusion - 370mg/1litre ; 5.26gram/1litre ; 55gram/1litre ; 5.02gram/1litre ; 300mg/1litre ; 3.68gram/1litre

Irland - engelsk - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - glucose monohydrate; sodium chloride; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate ; sodium gluconate - solution for infusion - 5 percent weight/volume - solutions affecting the electrolyte balance; electrolytes with carbohydrates

Irland - engelsk - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - sodium chloride; potassium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium acetate trihydrate ; glucose monohydrate - solution for infusion - solutions affecting the electrolyte balance; electrolytes with carbohydrates

Irland - engelsk - HPRA (Health Products Regulatory Authority)

baxter holding b.v. - sodium chloride; glucose monohydrate ph. eur.; sodium acetate, trihydrate; potassium chloride ph. eur.; magnesium chloride hexahydrate ph. eur. - solution for infusion - 55.00 gram(s)/litre - electrolytes with carbohydrates

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 20 mg/2ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 80 mg/8ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.